化瘀解毒汤对脓毒血症APACHEⅡ评分、ISTH DIC评分及外周血树突状细胞表面物质表达水平的影响

目的探讨化瘀解毒汤对脓毒血症患者APACHEⅡ评分、ISTH DIC评分及外周血树突状细胞表面物质表达水平的影响。方法将66例脓毒症患者随机分为对照组和化瘀解毒组,每组33例。对照组给予抗感染、补充血容量、积极治疗原发疾病、吸氧等综合治疗,化瘀解毒组在上述基础上加用化瘀解毒汤治疗,每日1剂,持续治疗2周。检测血清炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)]水平变化,应用急性生理与慢性健康状况评分Ⅱ(APACHEⅡ)、DIC评分评估脓毒症患者病情严重程度,应用流式细胞仪分析树突状细胞相关表面分子CD80、CD83、CD86表达情况,比较临床疗效。结果与治疗前比较,两组血清IL-6、TNF-α、PCT水平均降低(P<0.01),APACHEⅡ评分、ISTH DIC评分均降低(P<0.01),CD80、CD86水平均降低(P<0.01),CD83水平无差异(P>0.05);与对照组比较,化瘀解毒组血清IL-6、TNF-α、PCT水平均较低(P<0.01),APACHEⅡ评分、ISTH DIC评分均较低(P<0.01),CD80、CD86水平均较低(P<0.01),总有效率较高(P<0.01)。结论化瘀解毒汤辅助治疗脓毒血症疗效显著,可有效降低APACHEⅡ评分、ISTH DIC评分,可能与调节外周血树突状细胞表面物质表达有关。     

Validación de las escalas de APACHE II y SOFA en 2 cohortes de pacientes con sospecha de infección y sepsis,no ingresados en unidades de cuidados críticos

ObjectiveTo validate the APACHE II and SOFA scores in patients with suspected infection in clinical settings other than intensive care units.Materials and methodsA secondary analysis was performed on 2,530 adult patients participating in 2 cohort studies, with suspected infection as admission diagnosis within the first 24 h of hospitalization. The performance of both scoring systems was studied in order to set calibration and discrimination, respectively, on the outcomes such as mortality, admission to Intensive Care Unit, development of septic shock, or multiple organ dysfunctions.ResultsThe AUC-ROC values for mortality at discharge and on day 28 in the first cohort were around 0.50 for the SOFA and APACHE II scores; whereas for the second cohort the discrimination value was around 0.70. Calibration of both scoring systems for primary outcomes, according to Hosmer-Lemeshow test, showed p > .05 in the first cohort; while in the second cohort calibration it only showed a p > .05 in the case of the SOFA for mortality at hospital discharge.ConclusionThis validation study of SOFA and APACHE II scores in patients with suspected infection in-hospital units other than the Intensive Care Unit, showed no consistent performance for calibration and discrimination. Its application in emergency and in-hospital patients is limited.     

Impaired chemoreflex sensitivity in adult patients with multiple organ dysfunction syndrome—the potential role of disease severity

Objective The cardiac chemoreflex sensitivity is a powerful predictor of autonomic dysfunction in chronic heart failure and after myocardial infarction. The objective of the present study was to characterize cardiac chemoreflex sensitivity in patients with multiple organ dysfunction syndrome (MODS). We also aimed to elucidate the effect of the severity of MODS on the assessment of cardiac chemoreflex sensitivity.Design Prospective cohort study.Setting Twelve-bed medical intensive care unit in a university center.Patients Forty consecutively admitted patients with MODS during a 7-month period. Patients with MODS were identified by an APACHE II score of 20 or more. Sepsis was defined as a Sepsis Score, according to Elebute and Stoner, of 12 or more.Interventions The cardiac chemoreflex sensitivity was assessed using the regression of heart interval (ms) versus arterial oxygen pressure (mmHg).Measurements and results First, we established a new method to assess cardiac chemoreflex sensitivity and applied it to healthy controls and patients. Second, we found that cardiac chemoreflex sensitivity correlated with the severity of MODS as calculated by the APACHE II score (r²=0.34, p=0.001). This relation was best fitted by a model including minimum heart rate and standard bicarbonate in 24 h (r²=0.5, p<0.001) and Glasgow Coma Scale (r²=0.5, p=0.005). Age, however, did not significantly contribute (r²=0.001, p=0.8).Conclusions The calculation of cardiac chemoreflex sensitivity enabled us to quantify an important component of the cardiorespiratory interactions in patients with MODS. Severity of illness was a more pronounced determinant of impaired cardiac chemoreflex sensitivity than age. The quantification of the cardiorespiratory interactions by measuring the cardiac chemoreflex sensitivity has potential to identify a subgroup of patients with worse prognosis.     

血必净注射液对严重创伤后脓毒症患者凝血功能的影响

目的:研究并探讨血必净注射液对严重创伤后脓毒症患者凝血功能的影响。方法:将60例严重创伤后脓毒症患者随机分为两组,对照组30例给予常规综合治疗,治疗组30例在对照组治疗基础上早期加用血必净注射液,分别检测两组治疗前、治疗14d后的血小板计数、凝血酶原时间、活化部分凝血活酶时间,同时记录两组患者的急性生理和慢性健康状况评分(APACHEⅢ评分)和两组14d后病死率。结果:治疗组于治疗14d后上述检测指标改善且与对照组比较差异有显著性。两组APACHEⅢ评分均较治疗前下降且治疗14d后治疗组较对照组下降明显。治疗组较对照组病死率低但差异无显著性。结论:早期应用血必净注射液对严重创伤后脓毒症患者凝血功能有良性调节作用,从而在一定程度上改善预后。     

感染性休克患者血乳酸清除率与APACHEⅡ评分相关性分析

目的研究感染性休克患者血乳酸清除率与APACHEⅡ评分的相关性。方法对95例感染性休克患者入住重症监护病房6 h内进行动脉血乳酸浓度测定,根据APACHEⅡ评分分为两组：APACHEⅡ评分≥20分为A组,〈20分为B组;根据患者治疗结果,将患者分为存活组和死亡组。观察血乳酸清除率与患者病死率和APACHEⅡ评分的相关性。结果 A组患者血乳酸清除率明显高于B组（P〈0.01）,病死率明显低于B组患者;死亡组患者血乳酸清除率明显低于存活组患者（P〈0.01）;存活组及死亡组患者血乳酸清除率与APACHEⅡ评分均呈显著负相关性（P〈0.05）。结论乳酸清除率是判断感染性休克患者病情严重程度和预后的早期、敏感指标。     

Revised Acute Physiology and Chronic Health Evaluation score as a predictor of neurosurgery intensive care unit readmission: A case-controlled study

Purpose

Patients with neurologic system problems are among the most common patients readmitted to the intensive care unit (ICU). Readmission predictors for neurologic ICU patients have not been established. Previous research suggests that the Revised Acute Physiology and Chronic Health Evaluation (APACHE II) score is one indication of the critical status of ICU-admitted patients; however, the ability of the discharge APACHE II to predict readmission to the ICU requires further study. The purpose of this study was to investigate the ability of the APACHE II scoring system to predict ICU readmission of neurosurgical and ICU patients.

Materials and Methods

A retrospective case-controlled comparison study and a review of patient records for all patients admitted to 8 ICUs from January 2003 to June 2005 (N = 753) were conducted. Readmitted neurosurgery ICU patients were matched with 58 randomly selected nonreadmitted patients.

Results

Nine variables were significantly different between the readmission and case-controlled group. The APACHE II discharge score was the only significant predictor and was able to predict 18.6% of neurologic ICU readmissions. The risk of ICU readmission increased when the APACHE II score at the time of discharge exceeded 8.5 points.

Conclusions

The risk of ICU readmission of neurologic ICU patients can be predicted by determining APACHE II score upon ICU discharge.     

Comparison of the Rapid Emergency Medicine Score and APACHE II in Nonsurgical Emergency Department Patients

OBJECTIVES: To improve the Rapid Acute Physiology Score (RAPS) as a predictor of in-hospital mortality in the nonsurgical emergency department (ED) by including age and oxygen saturation, and to compare this new system, Rapid Emergency Medicine Score (REMS), with the Acute Physiology and Chronic Health Examination (APACHE II) with reference to predictive accuracy. METHODS: This was a prospective cohort study. One hundred sixty-two critically ill patients consecutively admitted to the intensive care unit (ICU) during the period of one year, and 865 nonsurgical patients presenting to an adult emergency department (ED) and admitted to a medical department of a 1200-bed university hospital during two months, were enrolled. For all entries to the ED, RAPS was calculated and developed to include noninvasive peripheral oxygen saturation and patient age (REMS), as well as laboratory tests (APACHE II). These scores were calculated for each patient. RESULTS: REMS was found to be superior to RAPS in predicting in-hospital mortality both in the critically ill patients admitted to the ICU and in the total sample (area under receiver-operating characteristic curve [AUC] 0.910 +/- 0.015 for REMS compared with 0.872 +/- 0.022 for RAPS, p < 0.001). An increase of 1 point in the 26-point REMS scale was associated with an odds ratio of 1.40 for in-hospital death (95% confidence interval = 1.36 to 1.45, p < 0.0001). The more advanced APACHE II was not found to be superior to REMS (AUC: 0.901 +/- 0.015, p = 0.218). CONCLUSIONS: RAPS could be improved as a predictor of in-hospital mortality in the nonsurgical ED by including oxygen saturation and patient age to the system. This new scoring system, REMS, had the same predictive accuracy as the well-established, but more complicated, APACHE II.